Publication:
Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center

dc.contributor.authorGÜNEŞ, BEGÜM
dc.contributor.authorONSUN, Nahide
dc.contributor.authorYABACI, AYŞEGÜL
dc.contributor.institutionauthorONSUN, NAHIDE
dc.contributor.institutionauthorGÜNEŞ, BEGÜM
dc.contributor.institutionauthorYABACI TAK, AYŞEGÜL
dc.date.accessioned2020-12-29T20:59:06Z
dc.date.available2020-12-29T20:59:06Z
dc.date.issued2020-12-01T00:00:00Z
dc.description.abstractThere have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated.
dc.identifier.citationONSUN N., GÜNEŞ B., YABACI A., -Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center-, DERMATOLOGIC THERAPY, 2020
dc.identifier.doi10.1111/dth.14623
dc.identifier.pubmed33274541
dc.identifier.scopus85097399307
dc.identifier.urihttp://hdl.handle.net/20.500.12645/27830
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/dth.14623
dc.identifier.wosWOS:000597427100001
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.titleRetention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center
dc.typeArticle
dspace.entity.typePublication
local.avesis.id2369cfd8-cfe7-4af1-bb18-6537da4ad4f4
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication1ebc9a95-ecf2-4c81-9f74-3c5fb32a9406
relation.isAuthorOfPublication55b107bb-ad4d-4030-9b11-5fea3f0e0391
relation.isAuthorOfPublication0e4de2a1-86eb-4e6c-ba74-a71afe7cba3b
relation.isAuthorOfPublication.latestForDiscovery55b107bb-ad4d-4030-9b11-5fea3f0e0391
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Retention and survival rate of etanercept in psoriasis over.pdf
Size:
2.14 MB
Format:
Adobe Portable Document Format
Description: